AE
Therapeutic Areas
Xspray Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Dasynoc (XS004 dasatinib) | Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) | NDA Submitted |
| XS003 (nilotinib) | Chronic Myeloid Leukemia (CML) | NDA Submitted |
| XS008 (axitinib) | Renal Cell Carcinoma | Preclinical/Development |
| XS025 (cabozantinib) | Renal Cell Carcinoma, Hepatocellular Carcinoma | Preclinical/Development |
Leadership Team at Xspray Pharma
PA
Per Andersson
Chief Executive Officer and Chief Scientific Officer
NA
Niklas Adenborg
Chief Financial Officer
AB
Anders Bladh
Board Member
MH
Markus Haeberlein
Board Member
CL
Christine Lind
Board Member
RM
Robert Molander
Board Member
AP
Anne Prener
Board Member
CS
Carl-Johan Spak
Board Member